
Sean E. Aeder
Examiner (ID: 17479)
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1642 |
| Total Applications | 1933 |
| Issued Applications | 905 |
| Pending Applications | 202 |
| Abandoned Applications | 853 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18377237
[patent_doc_number] => 20230152324
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => TUMOR-INTRINSIC NLRP3 INFLAMMASOME SIGNALING PATHWAY AS A GENETIC AND FUNCTIONAL BIOMARKER FOR IMMUNOTHERAPY RESPONSE
[patent_app_type] => utility
[patent_app_number] => 18/055406
[patent_app_country] => US
[patent_app_date] => 2022-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19552
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18055406
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/055406 | TUMOR-INTRINSIC NLRP3 INFLAMMASOME SIGNALING PATHWAY AS A GENETIC AND FUNCTIONAL BIOMARKER FOR IMMUNOTHERAPY RESPONSE | Nov 13, 2022 | Abandoned |
Array
(
[id] => 18565752
[patent_doc_number] => 20230256079
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => ONCOLYTIC VIRUS VACCINE AND DRUG FOR TREATING TUMORS BY COMBINING ONCOLYTIC VIRUS VACCINE WITH IMMUNE CELLS
[patent_app_type] => utility
[patent_app_number] => 18/054597
[patent_app_country] => US
[patent_app_date] => 2022-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11985
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054597
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054597 | Oncolytic virus vaccine and drug for treating tumors by combining oncolytic virus vaccine with immune cells | Nov 10, 2022 | Issued |
Array
(
[id] => 18693991
[patent_doc_number] => 20230324394
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => METHODS FOR THE DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA
[patent_app_type] => utility
[patent_app_number] => 18/054307
[patent_app_country] => US
[patent_app_date] => 2022-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22391
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054307
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/054307 | METHODS FOR THE DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA | Nov 9, 2022 | Pending |
Array
(
[id] => 19608903
[patent_doc_number] => 12157769
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-03
[patent_title] => Virus composition
[patent_app_type] => utility
[patent_app_number] => 18/047285
[patent_app_country] => US
[patent_app_date] => 2022-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 18
[patent_no_of_words] => 4693
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047285
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/047285 | Virus composition | Oct 17, 2022 | Issued |
Array
(
[id] => 18325137
[patent_doc_number] => 20230123265
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-20
[patent_title] => N6-Methyladenosine Regulators in Uterine Fibroids
[patent_app_type] => utility
[patent_app_number] => 17/968386
[patent_app_country] => US
[patent_app_date] => 2022-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4320
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17968386
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/968386 | N6-Methyladenosine Regulators in Uterine Fibroids | Oct 17, 2022 | Pending |
Array
(
[id] => 18649488
[patent_doc_number] => 20230295302
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => METHODS OF TREATING TUMOR
[patent_app_type] => utility
[patent_app_number] => 18/047216
[patent_app_country] => US
[patent_app_date] => 2022-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37644
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18047216
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/047216 | Methods of treating tumor | Oct 16, 2022 | Issued |
Array
(
[id] => 18256164
[patent_doc_number] => 20230083203
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-16
[patent_title] => NON-INVASIVE TEST TO PREDICT RESPONSE TO THERAPY IN COLORECTAL CANCER PATIENTS
[patent_app_type] => utility
[patent_app_number] => 18/046565
[patent_app_country] => US
[patent_app_date] => 2022-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3960
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046565
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/046565 | NON-INVASIVE TEST TO PREDICT RESPONSE TO THERAPY IN COLORECTAL CANCER PATIENTS | Oct 13, 2022 | Abandoned |
Array
(
[id] => 18988166
[patent_doc_number] => 20240060135
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-22
[patent_title] => THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
[patent_app_type] => utility
[patent_app_number] => 17/937102
[patent_app_country] => US
[patent_app_date] => 2022-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 132800
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17937102
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/937102 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER | Sep 29, 2022 | Abandoned |
Array
(
[id] => 18198470
[patent_doc_number] => 20230051989
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => CHIMERIC ANTIGEN RECEPTOR AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/932259
[patent_app_country] => US
[patent_app_date] => 2022-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24290
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17932259
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/932259 | Chimeric antigen receptor and methods of use thereof | Sep 13, 2022 | Issued |
Array
(
[id] => 19426162
[patent_doc_number] => 12085569
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-10
[patent_title] => Plasma autoantibody biomarkers for basal like breast cancer
[patent_app_type] => utility
[patent_app_number] => 17/940883
[patent_app_country] => US
[patent_app_date] => 2022-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 2259
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17940883
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/940883 | Plasma autoantibody biomarkers for basal like breast cancer | Sep 7, 2022 | Issued |
Array
(
[id] => 18421597
[patent_doc_number] => 20230176061
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => METHODS FOR DIAGNOSING HIGH-RISK CANCER USING POLYSIALIC ACID AND ONE OR MORE TISSUE-SPECIFIC BIOMARKERS
[patent_app_type] => utility
[patent_app_number] => 17/884465
[patent_app_country] => US
[patent_app_date] => 2022-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25546
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17884465
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/884465 | METHODS FOR DIAGNOSING HIGH-RISK CANCER USING POLYSIALIC ACID AND ONE OR MORE TISSUE-SPECIFIC BIOMARKERS | Aug 8, 2022 | Pending |
Array
(
[id] => 18666282
[patent_doc_number] => 11773160
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-10-03
[patent_title] => Immune-stimulating IL-2 fusion proteins
[patent_app_type] => utility
[patent_app_number] => 17/817886
[patent_app_country] => US
[patent_app_date] => 2022-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 24684
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 128
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17817886
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/817886 | Immune-stimulating IL-2 fusion proteins | Aug 4, 2022 | Issued |
| 17/817862 | DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES | Aug 4, 2022 | Abandoned |
Array
(
[id] => 18737950
[patent_doc_number] => 20230346852
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => APPLICATION OF BACTERIA IN PREPARATION OF SYNERGIST FOR IMMUNE CHECKPOINT INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 18/025640
[patent_app_country] => US
[patent_app_date] => 2022-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13692
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18025640
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/025640 | Application of bacteria in preparation of synergist for immune checkpoint inhibitor | Jul 11, 2022 | Issued |
Array
(
[id] => 18077433
[patent_doc_number] => 20220403045
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS
[patent_app_type] => utility
[patent_app_number] => 17/848694
[patent_app_country] => US
[patent_app_date] => 2022-06-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26648
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17848694
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/848694 | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers | Jun 23, 2022 | Issued |
Array
(
[id] => 19246801
[patent_doc_number] => 20240197785
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => PROCESSING OF TUMOR INFILTRATING LYMPHOCYTES
[patent_app_type] => utility
[patent_app_number] => 18/573111
[patent_app_country] => US
[patent_app_date] => 2022-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 106920
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -48
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18573111
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/573111 | PROCESSING OF TUMOR INFILTRATING LYMPHOCYTES | Jun 21, 2022 | Pending |
Array
(
[id] => 18110853
[patent_doc_number] => 20230003733
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => BIOMARKERS AND USES THEREOF FOR SELECTING IMMUNOTHERAPY INTERVENTION
[patent_app_type] => utility
[patent_app_number] => 17/846966
[patent_app_country] => US
[patent_app_date] => 2022-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26408
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17846966
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/846966 | BIOMARKERS AND USES THEREOF FOR SELECTING IMMUNOTHERAPY INTERVENTION | Jun 21, 2022 | Abandoned |
Array
(
[id] => 18167865
[patent_doc_number] => 20230034473
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-02
[patent_title] => METHODS OF TREATING FIBROBLAST GROWTH FACTOR 19-MEDIATED CANCERS AND TUMORS
[patent_app_type] => utility
[patent_app_number] => 17/843852
[patent_app_country] => US
[patent_app_date] => 2022-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25169
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843852
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/843852 | METHODS OF TREATING FIBROBLAST GROWTH FACTOR 19-MEDIATED CANCERS AND TUMORS | Jun 16, 2022 | Abandoned |
Array
(
[id] => 19418522
[patent_doc_number] => 20240294645
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => BISPECIFIC FUSION PROTEIN
[patent_app_type] => utility
[patent_app_number] => 18/570792
[patent_app_country] => US
[patent_app_date] => 2022-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13243
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18570792
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/570792 | BISPECIFIC FUSION PROTEIN | Jun 16, 2022 | Pending |
Array
(
[id] => 20309214
[patent_doc_number] => 20250326843
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-10-23
[patent_title] => BISPECIFIC ANTIBODY COMBINATION AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/571174
[patent_app_country] => US
[patent_app_date] => 2022-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10545
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18571174
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/571174 | BISPECIFIC ANTIBODY COMBINATION AND USE THEREOF | Jun 16, 2022 | Pending |